An Open-label, Single Dose, Pharmacokinetic Study of SR-T100 Gel (Containing 2.3% Solamargine in Solanum Undatum Plant Extract) in Patients With Actinic Keratosis

Trial Profile

An Open-label, Single Dose, Pharmacokinetic Study of SR-T100 Gel (Containing 2.3% Solamargine in Solanum Undatum Plant Extract) in Patients With Actinic Keratosis

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2015

At a glance

  • Drugs SR T100 (Primary)
  • Indications Actinic keratosis
  • Focus Pharmacokinetics
  • Sponsors G&E Herbal Biotechnology
  • Most Recent Events

    • 12 Aug 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 13 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top